Cyagen Biosciences Successfully Closes RMB 285 Million Series B Financing Amid Pandemic Challenges

Before the Spring Festival had even ended, the novel coronavirus brought the entire country to a standstill. In just a few short weeks, people witnessed what many recall as the nation’s most challenging period in recent memory. Nevertheless, Cyagen Biosciences and its investors did not halt their progress; they overcame various obstacles and completed all procedures remotely. On February 25, four prominent investment firms—China Merchants Zhiyuan, GF Qianhe, GF Xinde, and Guanghua Venture Capital—successfully closed Cyagen Biosciences’ Series B financing round, amounting to RMB 285 million.

Cyagen Biosciences is dedicated to integrating gene editing, biological big data, and laboratory mice and rats, leveraging engineering and informatics approaches to provide the most cost-effective, convenient, and accurate in vivo models for life science research, clinical therapeutic studies, and drug discovery and screening. Cyagen currently generates over 4,000 genetically engineered mouse and rat models annually, serving thousands of life science research institutions, clinical research organizations, CROs, pharmaceutical companies, and biotechnology firms worldwide. Its work has been cited more than 3,500 times in academic journals, including top-tier publications such as CNS (Cell, Nature, Science). Additionally, Cyagen provides the industry with free access to an increasingly comprehensive and powerful database of mouse and rat gene information, enabling researchers to query, design, and optimize gene-editing strategies online, as well as to compare research data and outcomes.

This round of funding will be used to expand Cyagen Biosciences’ business scope both domestically and internationally. The company plans to complete the construction of facilities totaling over 40,000 square meters in Central, North, South, and Southwest China within this year. Furthermore, Cyagen will vigorously advance its strategic depth in North America, Europe, and the Asia-Pacific region, strengthening its global footprint through deep collaborations with industry leaders in Europe and the United States.Cyagen is also transitioning from a company that has historically prioritized engineering to one that equally emphasizes both engineering and scientific innovation. It will significantly increase investment in research and development, recruit top-tier talent, continuously develop novel gene-editing methods, and substantially enrich its library of genetically engineered mouse resources. By establishing a product line of disease model mice through both introduction and in-house development, Cyagen aims to support drug discovery and screening in areas such as cancer immunotherapy, endocrinology, cardiovascular diseases, neuroscience, and infectious diseases. Additionally, the company will build CRO service platforms for humanized antibody mice, germ-free mice, and surgical model mice, as well as an AI-driven genomic big data platform. Over the next three years, Cyagen Biosciences strives to become a global leader in the model animal industry.